HighTower Advisors
TGTX icon

HighTower Advisors’s TG Therapeutics TGTX Stock Holding History

HighTower Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,500
Closed -$3K – 2507
2019
Q1 		$3K Buy
1,500
+500
+50% +$2.7K ﹤0.01% 2245
2018
Q4 		$1K Hold
1,000
– – ﹤0.01% 2197
2018
Q3 		$1K Buy
+1,000
New +$11.4K ﹤0.01% 2273

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HighTower Advisors's TGTX Position: Q1 2026 in Review

HighTower Advisors increased its TG Therapeutics (TGTX) stake by 8.6% in Q1 2026, buying an estimated $59.3K and bringing the position to 25,273 shares worth $840K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

HighTower Advisors first reported a position in TGTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $1M in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • HighTower Advisors held 25,273 shares of TG Therapeutics worth $840K as of Q1 2026.
  • HighTower Advisors bought 1,991 TG Therapeutics shares in Q1 2026, an estimated $59.3K.
  • TG Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2310 holding.
  • HighTower Advisors first reported a position in TG Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • HighTower Advisors's TG Therapeutics position peaked at $1M in Q3 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.